Maureen D. Dubreuil

Rheumatology

1 Boston Medical Ctr Pl
Boston, MA 02118

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 84 publications

Effect of Bimekizumab Treatment on Health Status, Work Productivity, and Productivity Costs Through 3 Years in Axial Spondyloarthritis and Psoriatic Arthritis.

Effect of Bimekizumab Treatment on Health Status, Work Productivity, and Productivity Costs Through 3 Years in Axial Spondyloarthritis and Psoriatic Arthritis.

Journal: The Journal of rheumatology

Published: July 01, 2026

Spondyloarthritis Research and Treatment Network Recommendations for the Referral of Adults With Chronic Back Pain and Suspected Axial Spondyloarthritis to a Rheumatologist.

Spondyloarthritis Research and Treatment Network Recommendations for the Referral of Adults With Chronic Back Pain and Suspected Axial Spondyloarthritis to a Rheumatologist.

Journal: ACR open rheumatology

Published: March 15, 2026

Bimekizumab treatment for sustained improvements in patient symptoms and health-related quality of life to 3 years in axial spondyloarthritis: results from the BE MOBILE studies and their open-label extension.

Bimekizumab treatment for sustained improvements in patient symptoms and health-related quality of life to 3 years in axial spondyloarthritis: results from the BE MOBILE studies and their open-label extension.

Journal: RMD open

Published: January 26, 2026

Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studies.

Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studies.

Journal: RMD open

Published: June 11, 2025

Targeted and biologic therapies and risk of total knee or hip replacement in axial spondyloarthritis and psoriatic arthritis.

Targeted and biologic therapies and risk of total knee or hip replacement in axial spondyloarthritis and psoriatic arthritis.

Journal: Clinical rheumatology

Published: May 21, 2025

Patient Diagnostic Journey and Time to Diagnosis in Axial Spondyloarthritis: A Retrospective Cohort Study Using US Claims Data.

Patient Diagnostic Journey and Time to Diagnosis in Axial Spondyloarthritis: A Retrospective Cohort Study Using US Claims Data.

Journal: Rheumatology and therapy

Published: May 15, 2025

Trends in Opioid Prescriptions in Individuals With Axial Spondyloarthritis in the United States and United Kingdom in the Last Two Decades: Analysis of Electronic Health Records and Insurance Claims Data.

Trends in Opioid Prescriptions in Individuals With Axial Spondyloarthritis in the United States and United Kingdom in the Last Two Decades: Analysis of Electronic Health Records and Insurance Claims Data.

Journal: Arthritis care & research

Published: May 15, 2025

Effect of Early Tumor Necrosis Factor Inhibitor Initiation on Chronic Opioid Use in Individuals With Axial Spondyloarthritis.

Effect of Early Tumor Necrosis Factor Inhibitor Initiation on Chronic Opioid Use in Individuals With Axial Spondyloarthritis.

Journal: Arthritis care & research

Published: April 29, 2025

Reply.

Reply.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: April 08, 2025

Real-World Use of Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Axial Spondyloarthritis in the United States: Persistence, Variables Associated With Persistence, and Dosing Variations.

Real-World Use of Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Axial Spondyloarthritis in the United States: Persistence, Variables Associated With Persistence, and Dosing Variations.

Journal: Pharmacoepidemiology and drug safety

Published: March 11, 2025

Diversity in Axial Spondyloarthritis Drug Trials: Enrollment by Sex, Race, Ethnicity, and Geographic Region.

Diversity in Axial Spondyloarthritis Drug Trials: Enrollment by Sex, Race, Ethnicity, and Geographic Region.

Journal: The Journal of rheumatology

Published: February 24, 2025

Comparative safety of biologic and targeted synthetic disease-modifying anti-rheumatic drugs for cardiovascular outcomes in rheumatoid arthritis.

Comparative safety of biologic and targeted synthetic disease-modifying anti-rheumatic drugs for cardiovascular outcomes in rheumatoid arthritis.

Journal: Rheumatology (Oxford, England)

Published: December 06, 2024

Showing 1-12 of 84

Last Updated: 09/26/2026